Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2011

View Archived Issues

Merck & Co. reports novel P2X7 receptor antagonists

Combined 96-week data disclosed from ECHO and THRIVE trials of rilpivirine versus efavirenz

Phase IIb data reported from SPRING-1 and VIKING trials of dolutegravir in HIV-1-infected adults

Japanese team describes novel putative biomarker of cognitive impairment in Alzheimer's disease

Phase III AQUIRE trial demonstrates benefits of aliskiren fumarate

Scientists reveal new potential biomarker of Alzheimer's disease

Hutchison MediPharma patents new HGF receptor inhibitors

Novel HIV protease inhibitors prepared by Hetero Research Foundation

Scientists at Novartis disclose novel beta-secretase 1 inhibitors

New GPR119 receptor agonists described by Nippon Chemiphar

Novel tryptase beta inhibitors patented

Chelsea Therapeutics reports on phase II droxidopa study

VaxOnco to sponsor phase I trial of Mayo Clinic cancer vaccine

Sublinox approved in Canada

TH-302 and bevacizumab enter clinical trial in astrocytoma

Almirall submits MAA to EMA for aclidinium bromide

ExonHit advances clinical validation of EHT Dx14

FDA issues safety alert regarding use of linezolid and methylene blue

Bayer Yakuhin launches Kogenate FS with Bio-Set injection 2000 in Japan

Merck & Co. to acquire rights to intravenous vernakalant

GlaxoSmithKline reports promising data from phase III ENABLE-1 study

EMA accepts for review Vanda's MAA for oral iloperidone formulation

Impax Pharmaceuticals fully enrolls ASCEND-PD phase III trial of IPX-066

TM-400 receives FDA orphan drug status

Aastrom reaches agreement with FDA on phase III REVIVE-CLI trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...